mitter-receptor combination (or combination between sympathomimetic drug and receptor) can be considered as the triggering of a multi-step sequential reaction leading to the cellular response. For example, norepinephrine, either released from the endings of the cardiac sympathetic nerves or of exogenous origin, reacts with receptors in the heart initiating reactions leading to cardiac acceleration and increased contractility. That is, the adrenergic receptor is part of the effector cell. It is not a binding site in either the nerve or the effector cell in which the transmitter or drug is held inactive. In addition to the specific adrenergic receptor there are other types of receptors, depicted in figure 1 as II and III, which react with other drugs.
The structure of the adrenergic receptors is not known, either biochemically or morphologically. What then is the basis for defining the "adrenergic receptor" as distinct from other receptors, as well as for distinguishing at least two types of adrenergic receptors? To elaborate on this question, gross physiologic response of the effector cell may not allow distinction between two types of receptors, e.g., activation of either of the hypothetical receptors I and II in figure 1 leads to augmented muscle contraction. Some distinction between receptors 16 Another effect of adrenergic stimuli which is antagonized by DCI and not by phenoxybenzamine is the activation of glycogen phosphorylase in the dog heart.'7 The relatively Circulation, Volume XXVIII, November 1963 Numbers in parentheses are number of specific activation of this enzyme system, which catalyzes the first step of glycogenolysis, by adrenergic stimuli and the selective blockade of this effect by DCI suggests that a beta type receptor subserves this adrenergic action.
The adrenergic receptors in blood vessels, as indicated above, are either alpha or beta. It is presumed that adrenergic vasoconstriction in the systemic circulation is alpha, in that isoproterenol has negligible arteriolar constrieting action and DCI does not block the vasoconstriction induced by potent amines. Adrenergic vasodilatation in the systemic circulation, mostly in skeletal muscle, is subserved by beta receptors since isoproterenol is the most potent amine and DCI blocks the effect.5 6 Mohlme-L-undholm and L-undholmls 19 have postulated that adrenergic vasodilatation in skeletal muscle is secondary to the lactic acid released in response to the glycogenolytic effect of adrenergic stimuli. If this hypothesis is correct, one need not assume a beta receptor specific to adrenergic amines in the vascular smooth muscle. Furchgott, 8 however, has presented evidence that adrenergically induced relaxation of smooth muscle can occur without increase in tissue lactic acid.
The available evidence suggests the existence of both alpha and beta receptors in the pulmonary circulation, that is, vasoconstriction mediated by alpha and vasodilatation mediated by beta receptors.20 21 
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